Cover Image

Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma

This prospective study examined the impact of genetic polymorphisms on the pharmacokinetics and clinical efficacy and safety of lenvatinib, a substrate of ATP-binding transporters, in a cohort of 48 Japanese patients with hepatocellular carcinoma (HCC). Pharmacokinetic studies were performed at the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hironao Okubo (Author), Hitoshi Ando (Author), Kei Ishizuka (Author), Jun-ichi Morishige (Author), Kenichi Ikejima (Author), Shuichiro Shiina (Author), Akihito Nagahara (Author)
Format:	Book
Published:	Elsevier, 2022-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma
by: Hironao Okubo, et al.
Published: (2022)

L-carnitine prevents lenvatinib-induced muscle toxicity without impairment of the anti-angiogenic efficacy
by: Zheng Jing, et al.
Published: (2023)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
by: Takeshi Hatanaka, et al.
Published: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
by: Matthew Man Pok Lee, et al.
Published: (2023)

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
by: Paula Soria-Chacartegui, et al.
Published: (2021)

A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014-2022)
by: Cong-Cong Wang, et al.
Published: (2023)

Gene Polymorphisms Affecting the Pharmacokinetics and Pharmacodynamics of Donepezil Efficacy
by: Jin Lu, et al.
Published: (2020)

Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen
by: Ioannis Loisios-Konstantinidis, et al.
Published: (2020)

Pharmacodynamic analysis of hypertension caused by lenvatinib using real‐world postmarketing surveillance data
by: Yuki Otani, et al.
Published: (2021)

Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma
by: Yukari Matsumoto, et al.
Published: (2022)

Lenvatinib-induced psoriasiform eruption and palmoplantar erythema in a patient with hepatocellular carcinoma
by: Rachel Sally, BA, et al.
Published: (2021)

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
by: Landon L. Chan, et al.
Published: (2024)

Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy
by: Xiaomi Li, et al.
Published: (2023)

Renal microangiopathy induced by lenvatinib in hepatocellular carcinoma: a case report and literature review
by: Cheng Xue, et al.
Published: (2024)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024)

Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC)
by: Oneeb Majid, et al.
Published: (2024)

Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers
by: Xinwen Wang, et al.
Published: (2021)

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
by: Ying He, et al.
Published: (2023)

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
by: Juanfang Liu, et al.
Published: (2021)

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
by: Chen B, et al.
Published: (2022)

Differences in the pharmacokinetics and steady-state blood concentrations of orally administered lenvatinib in adult and juvenile rats
by: Xiaoyue Du, et al.
Published: (2023)

circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma
by: Pengfei Zhang, et al.
Published: (2022)

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma
by: Nan Zhou, et al.
Published: (2023)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
by: Susanna Burckhardt, et al.
Published: (2011)

Isavuconazole Pharmacokinetics and Pharmacodynamics in Children
by: Hirsh Elhence, et al.
Published: (2022)

Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics
by: Bianca Vora, et al.
Published: (2021)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
by: Kaito Mimura, et al.
Published: (2022)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)

Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
by: Junji Furuse, et al.
Published: (2023)

Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study
by: Min Zhang, et al.
Published: (2024)

Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
by: Takamasa Ohki, et al.
Published: (2020)

Effects of three flavonoids on the metabolism of lenvatinib
by: Jinzhao Yang, et al.
Published: (2024)

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
by: Xu Y, et al.
Published: (2023)

The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics
by: Jiagen Wen, et al.
Published: (2019)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
by: Koen G. A. M. Hussaarts, et al.
Published: (2020)

Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics
by: Mercè Brunet, et al.
Published: (2022)

The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles
by: Andrzej Czyrski, et al.
Published: (2021)

Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
by: Kannan Sridharan, et al.
Published: (2021)

Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway
by: Yilan Huang, et al.
Published: (2024)

Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
by: Cheng Huang, et al.
Published: (2021)